The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2023

Filed:

Mar. 17, 2022
Applicant:

Vicore Pharma Ab, Stockholm, SE;

Inventors:

Ola Camber, Stockholm, SE;

Arnout Everaert, Mariakerke, SE;

Stefan Grudén, Stockholm, SE;

Assignee:

VICORE PHARMA AB, Stockholm, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/48 (2006.01); A61K 9/00 (2006.01); C07D 403/08 (2006.01);
U.S. Cl.
CPC ...
A61K 9/4808 (2013.01); A61K 9/0053 (2013.01); A61K 9/485 (2013.01); A61K 9/4816 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); C07D 403/08 (2013.01);
Abstract

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and/or a volume-based mean diameter, and/or a structural/particle density, that is/are similar to the weight- and/or volume-based mean diameter, and/or the structural/particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and/or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.


Find Patent Forward Citations

Loading…